Biohaven Intranasal Migraine Drug Gets FDA Approval + Moderna’s mRNA Influenza Vaccine

In this episode, which is the last episode for the year (the team will be back in January!), Ayesha discusses the FDA approval of Biohaven’s intranasal spray Zavegepant indicated for the acute treatment of migraines in adults. The drug is similar to the company oral dose tablet (ODT) Nurtec but is the first CGRP receptor antagonist in a nasal spray formulation. Some of the editorial team members shared their experiences with migraine headaches, and talked about the pros and cons of an intranasal spray for helping treat them.

The team also talked about the first results from an early-stage trial evaluating Moderna’s new mRNA-based influenza vaccine. After the success of its mRNA COVID-19 vaccine, the company got to work on a quadrivalent vaccine against influenza. The trial results showed that the vaccine had no serious safety concerns and that it elicits an immune response against the four different strains of the influenza virus in the vaccine. The results of this were a bit mixed as there were greater levels of neutralizing antibodies against influenza A strain antigens than influenza B strain antigens. Moderna is also planning for a triple target vaccine against COVID-19, influenza and RSV.

Read the full articles here: 

Biohaven Eyes FDA Approval for Second Migraine Drug Zavegepant After Promising Trial Results

Moderna Reveals Positive Results for its mRNA Influenza Vaccine

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured